Comparison of the clinical characteristics and outcomes associated with vancomycin-resistant Enterococcus faecalis and vancomycin-resistant E. faecium bacteremia
In published studies, cohorts of patients with bacteremia due to vancomycin-resistant Enterococcus (VRE) have predominantly been infected with Enterococcus faecium. Little is known about the epidemiology and outcomes associated with bacteremia due to VR Enterococcus faecalis. A retrospective study of isolates obtained from January 2008 to October 2010 was conducted at Detroit Medical Center (DMC). Unique patients with blood cultures positive for VRE were reviewed. Outcomes were analyzed using logistic regression. During the study period, 105 cases of bacteremia due to VR E. faecalis and 197 cases of bacteremia due to VR E. faecium were identified. The mean age in the study cohort was 61.5 ± 15 years; 162 subjects (53.6%) were male. After controlling for a propensity score, bacteremia due to VR E. faecalis was associated with >2-fold-lower in-hospital mortality than bacteremia due to VR E. faecium. Interestingly, bacteremia due to VR E. faecalis was associated with longer hospital stay after VRE isolation, although total length of stay was similar for groups with VR E. faecalis and VR E. faecium. Bacteremia due to VR E. faecalis was associated with a >2-fold-lower risk for mortality than bacteremia due to VR E. faecium, possibly due to the availability of β-lactam therapeutics for treatment of VR E. faecalis.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2012 |
|---|---|
| Erschienen: |
2012 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:56 |
|---|---|
| Enthalten in: |
Antimicrobial agents and chemotherapy - 56(2012), 5 vom: 28. Mai, Seite 2452-8 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Hayakawa, Kayoko [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
6Q205EH1VU |
|---|
| Anmerkungen: |
Date Completed 17.08.2012 Date Revised 21.10.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1128/AAC.06299-11 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM215609840 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM215609840 | ||
| 003 | DE-627 | ||
| 005 | 20231224025845.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2012 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1128/AAC.06299-11 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0718.xml |
| 035 | |a (DE-627)NLM215609840 | ||
| 035 | |a (NLM)22354290 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Hayakawa, Kayoko |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Comparison of the clinical characteristics and outcomes associated with vancomycin-resistant Enterococcus faecalis and vancomycin-resistant E. faecium bacteremia |
| 264 | 1 | |c 2012 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 17.08.2012 | ||
| 500 | |a Date Revised 21.10.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a In published studies, cohorts of patients with bacteremia due to vancomycin-resistant Enterococcus (VRE) have predominantly been infected with Enterococcus faecium. Little is known about the epidemiology and outcomes associated with bacteremia due to VR Enterococcus faecalis. A retrospective study of isolates obtained from January 2008 to October 2010 was conducted at Detroit Medical Center (DMC). Unique patients with blood cultures positive for VRE were reviewed. Outcomes were analyzed using logistic regression. During the study period, 105 cases of bacteremia due to VR E. faecalis and 197 cases of bacteremia due to VR E. faecium were identified. The mean age in the study cohort was 61.5 ± 15 years; 162 subjects (53.6%) were male. After controlling for a propensity score, bacteremia due to VR E. faecalis was associated with >2-fold-lower in-hospital mortality than bacteremia due to VR E. faecium. Interestingly, bacteremia due to VR E. faecalis was associated with longer hospital stay after VRE isolation, although total length of stay was similar for groups with VR E. faecalis and VR E. faecium. Bacteremia due to VR E. faecalis was associated with a >2-fold-lower risk for mortality than bacteremia due to VR E. faecium, possibly due to the availability of β-lactam therapeutics for treatment of VR E. faecalis | ||
| 650 | 4 | |a Comparative Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Anti-Bacterial Agents |2 NLM | |
| 650 | 7 | |a beta-Lactams |2 NLM | |
| 650 | 7 | |a Vancomycin |2 NLM | |
| 650 | 7 | |a 6Q205EH1VU |2 NLM | |
| 700 | 1 | |a Marchaim, Dror |e verfasserin |4 aut | |
| 700 | 1 | |a Martin, Emily T |e verfasserin |4 aut | |
| 700 | 1 | |a Tiwari, Namita |e verfasserin |4 aut | |
| 700 | 1 | |a Yousuf, Adnan |e verfasserin |4 aut | |
| 700 | 1 | |a Sunkara, Bharath |e verfasserin |4 aut | |
| 700 | 1 | |a Pulluru, Harish |e verfasserin |4 aut | |
| 700 | 1 | |a Kotra, Harikrishna |e verfasserin |4 aut | |
| 700 | 1 | |a Hasan, Asma |e verfasserin |4 aut | |
| 700 | 1 | |a Bheemreddy, Suchitha |e verfasserin |4 aut | |
| 700 | 1 | |a Sheth, Puja |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Dae-Won |e verfasserin |4 aut | |
| 700 | 1 | |a Kamatam, Srinivasa |e verfasserin |4 aut | |
| 700 | 1 | |a Bathina, Pradeep |e verfasserin |4 aut | |
| 700 | 1 | |a Nanjireddy, Priyanka |e verfasserin |4 aut | |
| 700 | 1 | |a Chalana, Indu K |e verfasserin |4 aut | |
| 700 | 1 | |a Patel, Satyam |e verfasserin |4 aut | |
| 700 | 1 | |a Kumar, Sarwan |e verfasserin |4 aut | |
| 700 | 1 | |a Vahia, Amit |e verfasserin |4 aut | |
| 700 | 1 | |a Ku, Kimberly |e verfasserin |4 aut | |
| 700 | 1 | |a Yee, Victoria |e verfasserin |4 aut | |
| 700 | 1 | |a Swan, Jessie |e verfasserin |4 aut | |
| 700 | 1 | |a Pogue, Jason M |e verfasserin |4 aut | |
| 700 | 1 | |a Lephart, Paul R |e verfasserin |4 aut | |
| 700 | 1 | |a Rybak, Michael J |e verfasserin |4 aut | |
| 700 | 1 | |a Kaye, Keith S |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Antimicrobial agents and chemotherapy |d 1972 |g 56(2012), 5 vom: 28. Mai, Seite 2452-8 |w (DE-627)NLM000026506 |x 1098-6596 |7 nnns |
| 773 | 1 | 8 | |g volume:56 |g year:2012 |g number:5 |g day:28 |g month:05 |g pages:2452-8 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1128/AAC.06299-11 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 56 |j 2012 |e 5 |b 28 |c 05 |h 2452-8 | ||